References
- Adis Editors. (2012). Manage drug-induced parkinsonism through early recognition of the condition and discontinuation of the causative agent. Drugs & Therapy Perspectives, 28(12), 20–23. doi:10.1007/BF03262145
- Ahlenius, S., & Ericson, E. (2001). Scopolamine does not restore normal conditioned avoidance performance in raclopride-treated rats. Journal of Neural Transmission, 108, 415–430.
- Ali, T., Sisay, M., Tariku, M., Mekuria, A. N., & Desalew, A. (2021). Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies. Plos one, 16(9), e0257129.
- Alty, J., Cosgrove, J., Thorpe, D., & Kempster, P. (2017). How to use pen and paper tasks to aid tremor diagnosis in the clinic. Pract Neurol, 17(6), 456–463. doi:10.1136/practneurol-2017-001719
- Alves, G., Forsaa, E., Pedersen, K. F., Gjerstad, M., & Larsen, J. (2008). Epidemiology of Parkinson’s disease. Journal of neurology, 255, 18–32. doi:10.1007/s00415-008-5004-3
- Anand, R., Pandey, S., Garg, R. K., Singh Malhotra, H., Shrivastava, S., Kar, S. K., … Rizvi, I. (2023). Phenomenology, quality of life, and predictors of reversibility in patients with drug-induced movement disorders: a prospective study. CNS Spectr, 28(5), 534–536. doi:10.1017/s1092852922001201
- Baez, M. A., & Avery, J. (2011). Improvement in drug-induced parkinsonism with electro-convulsive therapy. The American Journal of Geriatric Pharmacotherapy, 9(3), 190–193.
- Bamford, I. J., & Bamford, N. S. (2019). The Striatum’s Role in Executing Rational and Irrational Economic Behaviors. Neuroscientist, 25(5), 475–490. doi:10.1177/1073858418824256
- Beaulieu, J.-M., & Caron, M. G. (2008). Looking at lithium: molecular moods and complex behaviour. Molecular interventions, 8 (5), 230.
- Benítez-Rivero, S., Lama, M. J., Huertas-Fernández, I., de Toledo, P. Á., Cáceres-Redondo, M. T., Martín-Rodríguez, J. F., … Mir, P. (2014). Clinical features and neuropsychological profile in vascular parkinsonism. Journal of the neurological sciences, 345(1-2), 193–197.
- Blanchet, P. J., & Kivenko, V. (2016). Drug-induced parkinsonism: diagnosis and management. Journal of parkinsonism and restless legs syndrome, 83–91.
- Bohlega, S., & Al-Foghom, N. B. (2013). Drug-induced Parkinson’s disease. A clinical review. Neurosciences, 18 3, 215–221.
- Brigo, F., Erro, R., Marangi, A., Bhatia, K., & Tinazzi, M. (2014). Differentiating drug-induced parkinsonism from Parkinson’s disease: an update on non-motor symptoms and investigations. Parkinsonism & related disorders, 20(8), 808–814.
- Burkhard, P. R. (2014). Acute and subacute drug-induced movement disorders. Parkinsonism & related disorders, 20, S108–S112.
- Caroff, S. N., Mu, F., Ayyagari, R., Schilling, T., Abler, V., & Carroll, B. (2018). Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia. BMC psychiatry, 18, 1–13.
- Chen, Y., Lu, T., Jiang, X., & Huang, X. (2021). The effectiveness of specialized nursing interventions for patients with Parkinson disease: A randomized controlled study protocol. Medicine, 100(2), e23972.
- Cunningham Owens, D. G. (2014). Parkinsonism. In D. G. Cunningham Owens (Ed.), A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs (2 ed., pp. 68-133). Cambridge: Cambridge University Press.
- Dallapiazza, R., Vloo, P., Fomenko, A., Lee, D., Hamani, C., Munhoz, R., … Kalia, S. (2018). Considerations for Patient and Target Selection in Deep Brain Stimulation Surgery for Parkinson’s Disease. In.
- de Germay, S., Montastruc, F., Carvajal, A., Lapeyre-Mestre, M., & Montastruc, J.-L. (2020). Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism & related disorders, 70, 55–59.
- Diaz-Martinez, A., Benassinni, O., Ontiveros, A., Gonzalez, S., Salin, R., Basquedano, G., & Martinez, R. A. (1998). A randomized, openlabel comparison of venlafaxine and fluoxetine in depressed outpatients. Clinical therapeutics, 20(3), 467–476.
- Draoui, A., El Hiba, O., Aimrane, A., El Khiat, A., & Gamrani, H. (2020). Parkinson’s disease: from bench to bedside. Revue Neurologique, 176(7-8), 543–559.
- Druschky, K., Bleich, S., Grohmann, R., Engel, R. R., Toto, S., Neyazi, A., … Stübner, S. (2020). Severe parkinsonism under treatment with antipsychotic drugs. European Archives of Psychiatry and Clinical Neuroscience, 270, 35–47.
- Esper, C. D., & Factor, S. A. (2008). Failure of recognition of drug-induced parkinsonism in the elderly. Movement disorders: official journal of the Movement Disorder Society, 23(3), 401–404.
- Faber, R., & Trimble, M. R. (1991). Electro-convulsive therapy in Parkinson’s disease and other movement disorders. Movement disorders: official journal of the Movement Disorder Society, 6(4), 293–303.
- Factor, S. A. (2004). Lithium-induced movement disorders. NEUROLOGICAL DISEASE AND THERAPY, 62, 209–232.
- Fountoulakis, K. N., Tohen, M., & Zarate Jr, C. A. (2022). Lithium treatment of Bipolar disorder in adults: A systematic review of randomized trials and meta-analyses. European Neuropsychopharmacology, 54, 100–115.
- Friedman, J. H. (2014). Challenges in our understanding of neuroleptic induced parkinsonism. Parkinsonism & related disorders, 20(12), 1325–1328.
- Gallagher, S., & Bouchard, L. (2023). Nurse practitioner educational preparation and confidence related to managing antipsychotic medications and associated drug-induced movement disorders. Journal of the American Association of Nurse Practitioners, 10.1097.
- Galoppin, M., Berroir, P., Soucy, J. P., Suzuki, Y., Lavigne, G. J., Gagnon, J. F., … Blanchet, P. J. (2020). Chronic neuroleptic-induced parkinsonism examined with positron emission tomography. Movement Disorders, 35 (7), 1189–1198.
- Gershanik, O. S. (1994). Drug-induced parkinsonism in the aged: recognition and prevention. Drugs & aging, 5, 127–132.
- Gordon, J. H., Gorski, R. A., Borison, R. L., & Diamond, B. I. (1980). Postsynaptic efficacy of dopamine: possible suppression by estrogen. Pharmacology Biochemistry and Behavior, 12 (4), 515–518.
- Hirose, G. (2006). Drug induced parkinsonism: a review. Journal of neurology, 253, iii22–iii24.
- Holroyd, S., & Smith, D. (1995). Disabling parkinsonism due to lithium: a case report. Journal of Geriatric Psychiatry and Neurology, 8(2), 118–119.
- Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry, 55(3), 181–184. doi:10.1136/jnnp.55.3.181
- Kasten, M., Brüggemann, N., König, I. R., Doerry, K., Steinlechner, S., Wenzel, L., … Lencer, R. (2011). Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility. Psychopharmacology, 214, 729–736.
- Korczyn, A. D. (2015). Vascular parkinsonism—characteristics, pathogenesis and treatment. Nature Reviews Neurology, 11 (6), 319–326.
- Kowal, S. L., Dall, T. M., Chakrabarti, R., Storm, M. V., & Jain, A. (2013). The current and projected economic burden of Parkinson’s disease in the United States. Movement Disorders, 28(3), 311–318.
- Kumsa, A., Agenagnew, L., Alemu, B., & Girma, S. (2020). Psychotropic medications induced parkinsonism and akathisia in people attending follow-up treatment at Jimma Medical Center, Psychiatry Clinic. Plos one, 15(7), e0235365.
- Lim, T., Ahmed, A., Itin, I., Gostkowski, M., Rudolph, J., Cooper, S., & Fernandez, H. (2013). Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson’s disease? International Journal of Neuroscience, 123(3), 170–174.
- López-Sendón, J., Mena, M. A., & G de Yébenes, J. (2013). Drug-induced parkinsonism. Expert opinion on drug safety, 12(4), 487–496.
- López-Sendón, J. L., Mena, M. A., & de Yébenes, J. G. (2012). Drug-induced parkinsonism in the elderly: incidence, management and prevention. Drugs & aging, 29, 105–118.
- Martí-Massó, J. F., & Poza, J. J. (1998). Cinnarizine-induced parkinsonism: ten years later. Movement Disorders, 13(3), 453–456.
- Mena, M. A., & De Yébenes, J. G. (2006). Drug-induced parkinsonism. Expert opinion on drug safety, 5(6), 759–771. Retrieved from https://www.tandfonline.com/doi/pdf/10.1517/14740338.5.6.759
- Moleman, P., Janzen, G., Von Bargen, B. A., Kappers, E. J., Pepplinkhuizen, L., & Schmitz, P. (1986). Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol. The American journal of psychiatry, 143(2), 232–234.
- Mukilan, D., Praveen, D., Chowdary, P. R., & Aanandhi, M. V. (2018). Drug-induced parkinsonism: a review. Drug Invent Today, 10 (2), 212–215.
- Pandey, S., Pitakpatapee, Y., Saengphatrachai, W., Chouksey, A., Tripathi, M., & Srivanitchapoom, P. (2023). Drug-Induced Movement Disorders. Paper presented at the Seminars in Neurology.
- Pitton Rissardo, J., & Caprara, A. L. F. (2023). Neuroimaging Techniques in Differentiating Parkinson’s Disease from Drug-Induced Parkinsonism: A Comprehensive Review. Clinics and Practice, 13(6), 1427–1448.
- Pitton Rissardo, J., Vora, N., Mathew, B., Kashyap, V., Muhammad, S., & Fornari Caprara, A. (2023). Overview of Movement Disorders Secondary to Drugs. Clinics and Practice, 13, 959–976. doi:10.3390/clinpract13040087
- Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., … Deuschl, G. (2015). MDS clinical diagnostic criteria for Parkinson’s disease. Movement Disorders, 30(12), 1591–1601. doi:https://doi.org/10.1002/mds.26424
- Powell, A., Gallur, L., Koopowitz, L., & Hayes, M. W. (2020). Parkinsonism in the psychiatric setting: An update on clinical differentiation and management. BMJ Neurology Open, 2(1).
- Prell, T., Siebecker, F., Lorrain, M., Tönges, L., Warnecke, T., Klucken, J., … Lorenzl, S. (2020). Specialized staff for the care of people with Parkinson’s disease in Germany: an overview. Journal of Clinical Medicine, 9(8), 2581.
- Radder, D. L., de Vries, N. M., Riksen, N. P., Diamond, S. J., Gross, D., Gold, D. R., … Lennaerts, H. H. (2019). Multidisciplinary care for people with Parkinson’s disease: the new kids on the block! Expert review of neurotherapeutics, 19(2), 145–157.
- Reeve, A., Simcox, E., & Turnbull, D. (2014). Ageing and Parkinson’s disease: why is advancing age the biggest risk factor? Ageing research reviews, 14, 19–30.
- Rissardo, J. P., & Caprara, A. L. F. (2023). Predictors of Drug-Induced Parkinsonism. APIK Journal of Internal Medicine.
- Rogers, R., Hartigan, S. E., & Sanders, C. E. (2021). Identifying mental disorders in primary care: diagnostic accuracy of the connected mind fast check (CMFC) electronic screen. Journal of clinical psychology in medical settings, 28(4), 882–896.
- Savica, R., Grossardt, B. R., Bower, J. H., Ahlskog, J. E., Mielke, M. M., & Rocca, W. A. (2017). Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study. Movement Disorders, 32(2), 227–234.
- Sethi, K. D. (2003). Differential Diagnosis of Parkinsonism.
- Shin, H. W., & Chung, S. J. (2012). Drug-induced parkinsonism. J Clin Neurol, 8(1), 15–21. doi:10.3988/jcn.2012.8.1.15
- Tachibana, K., Matsuura, K., Shindo, A., Matsuyama, H., Ii, Y., Taniguchi, A., & Tomimoto, H. (2020). Symptomatic characteristics of parkinson’s disease induced by neuroleptic drugs, based on a functional neuroimaging diagnosis. Internal Medicine, 59(4), 485–490.
- Undeberg, M. R., McKeirnan, K. C., & Easley, D. (2022). Respecting the patient’s choice: a case of possible drug-induced parkinsonism. Pharmacy, 10 (1), 10.
- van Munster, M., Stümpel, J., Thieken, F., Ratajczak, F., Rascol, O., Fabbri, M., … Pedrosa, D. J. (2022). The role of Parkinson nurses for personalizing Care in Parkinson’s disease: a systematic review and Meta-analysis. Journal of Parkinson’s Disease, 12 (6), 1807–1831.
- Vasquez Builes, S., Salazar, C., Tieck-Fernández, M., Rojas-Gallego, I., & Díaz Silva, G. (2021). Drug-induced parkinsonism: what should a psychiatrist know? Revista Mexicana de Neurociencia, 22. doi:10.24875/RMN.20000010